Evidence map›Paper›PMID 41889560›Full record

ArticleJournal of clinical & experimental immunology2026

Benzoate Drugs for Traumatic Brain Injury.

Swarupa Pahan, Kalipada Pahan

Abstract read
In one paragraph

Article in Journal of clinical & experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Swarupa PahanDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, USA.
Kalipada PahanDivision of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, USA.

Funding

Muscle building supplement HMB for remyelinationR01AT010980 · NCCIH · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2020 to 2024
$2.7M
BLRD VA I01 BX005002BLRD VA I01 BX005613BLRD VA IK6 BX004982NCCIH NIH HHS R01 AT010980
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is an acute disorder with prolonged complexities that affirm to be the leading cause of deaths and disabilities in US. The pathophysiology of TBI comprises of multiple complex processes. An impactful insult results in tissue damage, neuroinflammation, impaired cerebral blood flow, BBB disruption, and demyelination, leading to neurodegeneration and functional impairments. There are no specific treatments for TBI. Recent studies highlight the potential efficacy of the following benzoates for attenuating TBI pathologies in rodents: Sodium benzoate, a metabolite of cinnamon, a widely used food additive and a Food and Drug Administration (FDA)-approved drug for glycine encephalopathyGlyceryl tribenzoate, FDA-approved flavoring element being used in food and food packing productions In this review, we have made a genuine attempt to evaluate the significance of these two benzoates as prospective therapeutic options for TBI.

Indexed as

Cognitive DysfunctionDrug RepurposingGlial ActivationGlyceryl TribenzoateNeurodegenerationNeuroprotectionOxidative StressSodium BenzoateTraumatic Brain Injury

Identifiers

PMID41889560
PMCPMC13015919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.